Skip to main content
Scott Woods, MD, Psychiatry, New Haven, CT, Yale-New Haven Hospital

ScottWWoodsMD

Psychiatry New Haven, CT

Professor, Psychiatry, Yale University School of Medicine

Dr. Woods is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Woods' full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital/McLean Hospital
    Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1980 - 1984
  • Baylor College of Medicine
    Baylor College of MedicineClass of 1978

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 1984 - 2024
  • TX State Medical License
    TX State Medical License 1979 - 1984
  • American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Use of Machine Learning to Determine Deviance in Neuroanatomical Maturity Associated with Future Psychosis in Youths at Clinically High Risk  
    Daniel H Mathalon, Thomas McGlashan, Scott W Woods, Diana Perkins, Ming Tsuang, Carrie E Bearden, Kristin Cadenhead, JAMA

Press Mentions

  • Feinstein Institutes Researchers Help Lead $52M Study of Schizophrenia in High-Risk Youth
    Feinstein Institutes Researchers Help Lead $52M Study of Schizophrenia in High-Risk YouthNovember 16th, 2020
  • Accelerating Science to Advance Early Interventions for Schizophrenia
    Accelerating Science to Advance Early Interventions for SchizophreniaOctober 30th, 2020
  • Scientists Awarded $52M NIH Grant to Study Schizophrenia Cause and Effect
    Scientists Awarded $52M NIH Grant to Study Schizophrenia Cause and EffectSeptember 15th, 2020
  • Join now to see all

Grant Support

  • 8/8-Predictors And Mechanisms Of Conversion To PsychosisNational Institute Of Mental Health2008–2012
  • Huperzine For Cognitive And Functional Impairment In SchizophreniaNational Institute Of Mental Health2008–2010
  • Enhancing The Prospective Prediction Of PsychosisNational Institute Of Mental Health2003–2007
  • Tardive Dyskinesia Incidence And Atypical AntipsychoticNational Institute Of Mental Health2001–2004
  • Treatment Of Panic Disorder--Long Term StrategiesNational Institute Of Mental Health1999–2003
  • Tardive Dyskinesia Incidence And Atypical AntipsychoticsNational Institute Of Mental Health2000
  • Atypical Antipsychotic Medications--Outcomes And CostsNational Institute Of Mental Health1997–2000
  • Glutaminergic Agents For Cocaine AbuseNational Institute On Drug Abuse1996–1998
  • CT DMH Yale Medication Effectiveness Research ProgramNational Institute Of Mental Health1994–1998
  • Multictr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1996
  • Multi-Ctr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1995
  • Treatment Study Of Panic DisorderNational Institute Of Mental Health1994
  • Rapid Benzodiazepine Detoxification Using FlumazenilNational Institute On Drug Abuse1993–1994
  • Multi-Ctr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1990–1993
  • Effects Of Yohimbine On RCBF In Panic DisorderNational Institute Of Mental Health1989

Hospital Affiliations